Turning Knowledge into New Medicines

The impact of modern cancer genetics, biochemistry, and biology is beginning to change the practice of medicine with both biopharmaceuticals and small-molecule drugs. This started with the first oncogene and tumor suppressor gene discoveries, dissection of cell division cycle and growth signalling, and molecular descriptions of tumor angiogenesis and metastatic spread.

Our approach to selecting the most promising targets for drug discovery is guided by scientific innovation as much as feasibility for the design of small molecule drugs and/or biopharmaceuticals, both of which are areas of considerable corporate expertise at Boehringer Ingelheim.

Targeting Cancer

We pursue the hunt for new cancer drugs along several fronts, including these:

• Cell surface receptor signalling
• Cell cycle regulation
• Tumor cell survival and drug resistance
• Tumor angiogenesis